The Joint Mobile Emerging Disease Clinical Capability (JMEDICC) laboratory approach: Capabilities for high-consequence pathogen clinical research

by Prossy Naluyima, Willy Kayondo, Chi Ritchie, Joseph Wandege, Sharon Kagabane, Lydia Tumubeere, Brenda Kusiima, Daniel Kibombo, Sharon Atukunda, Christine Nanteza, Harriet Nabirye, Francis Bunjo Mugabi, Sarah Namuyanja, Christopher Hatcher, Hypaitia Rauch, Moses Mukembo, Patrick Musinguzi, JMEDICC Consortium , Nathan Sanders, Elizabeth Turesson, Christian Cando, Richard Walwema, Derrick Mimbe, Janice Hepburn, Danielle Clark, Mohammed Lamorde, Hannah Kibuuka, Saima Zaman, Anthony P. Cardile, Karen A. Martins Following the 2013–2016 Ebola virus outbreak in West Africa, numerous groups advocated for the importance of executing clinical trials in outbreak settings. The difficulties associated with obtaining reliable data to support regulatory approval of investigational vaccines and therapeutics during that outbreak were a disappointment on a research and product development level, as well as on a humanitarian level. In response to lessons learned from the outbreak, the United States Department of Defense established a multi-institute project called the Joint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC). JMEDICC’s primary objective is to establish the technical capability in western Uganda to execute clinical trials during outbreaks of high-consequence pathogens such as the Ebola virus. A critical component of clinical trial execution is the establishment of laborato ry operations. Technical, logistical, and political challenges complicate lab...
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research

Related Links:

Ebolavirus (EBOV) infection in humans causes severe hemorrhagic fevers with high mortality rates that range from 30 to 80% as shown in different outbreaks. Thus the development of safe and efficacious EBOV vaccines remains an important goal for biomedical research. We have shown in early studies that immunization with insect cell-produced EBOV virus-like particles (VLPs) is able to induce protect vaccinated mice against lethal EBOV challenge. In the present study, we investigated immune responses induced by Ebola VLPs via two different routes, intramuscular and intradermal immunizations, in guinea pigs. Analyses of antibod...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Okay, I'm not an epidemiologist or a virologist. But I do know something about those subjects, I'm a public health professor, and I am an expert in clinical communication and risk communication. So I'm going to offer some observations that I hope will help people keep this public health scare in proper perspective and maybe be of practical use.There are two important parameters we need to understand the risk caused by any communicable disease. I'm going to broadly say transmissibility, and the probability that exposure will lead to serious disease.We often see transmissibility represented as a single number, called R0 or &...
Source: Stayin' Alive - Category: American Health Source Type: blogs
TTP, a technology company based in Melbourn, UK, is developing a handheld PCR (polymerase chain reaction) diagnostic device that can rapidly detect influenza viruses, and one day other viruses, in samples of nasal mucus. The company claims that the s...
Source: Medgadget - Category: Medical Devices Authors: Tags: Diagnostics Exclusive Public Health Source Type: blogs
ConclusionWith advanced training and adherence to infection prevention and control practices, clinical interventions, including critical care, are feasible and safe to perform in critically ill patients. With specific anti-Ebola medications, most patients can survive Ebola virus infection.
Source: Intensive Care Medicine - Category: Intensive Care Source Type: research
By Dr. Lisa Stone, Epidemiology Adviser ; Robert Salerno, Director, Global Health Security Publio Gonzalez, a biologist with the Gorgas Institute, holds a bat in Meteti, Panama, June 6, 2018, as part an Emerging Infectious Diseases Training Event (U.S. Air Force photo by Senior Airman Dustin Mullen).February 11, 2020A disease spillover event, when a virus moves from animal to human hosts, can cause significant human illness. The coronavirus (COVID-19) seems to have spilled over sometime in late 2019, at a wildlife market in Wuhan, China, leading to more than 40,000 confirmed cases and at least 910 reported deaths&nbs...
Source: IntraHealth International - Category: International Medicine & Public Health Authors: Tags: Infectious Diseases Global Health Security Source Type: news
NEW BRUNSWICK, N.J., February 11, 2020 – Johnson &Johnson today announced that its Janssen Pharmaceutical Companies will further expedite its investigational coronavirus vaccine program through an expanded collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health &Human Services. The collaborative partnership with BARDA builds on Johnson &Johnson’s multipronged response to the new coronavirus disease (COVID-19) outbreak. In addition to Janssen’s effor...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
As the deadly 2019-nCov coronavirus spreads, raising fears of a worldwide pandemic, researchers and startups are using artificial intelligence and other technologies to predict where the virus might appear next — and even potentially sound the alarm before other new, potentially threatening viruses become public health crises. “What we’re doing currently with Coronavirus is really trying to get an understanding of what’s happening on the ground through as many sources as we can get our hands on,” says John Brownstein, chief innovation officer at Boston Children’s Hospital and a professor...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV coronavirus MSFTAI2019 onetime Source Type: news
Pandemics are perversely democratic. They’re nasty, lethal and sneaky, but they don’t discriminate. No matter your age, ethnicity, religion, gender, or nation, you’re a part of the pathogenic constituency. That shared vulnerability, and the resulting human collectivism—a universal response to a universal threat—is newly and vividly evident in the face of the now-global outbreak of the novel coronavirus known as 2019-nCoV. As of writing, there have been over 30,000 diagnosed cases and over 630 related deaths. A virus that emerged in a single city, Wuhan, China—indeed, in a single crowded ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV Infectious Disease Source Type: news
“Everyone knows that pestilences have a way of recurring in the world,” observes Albert Camus in his novel The Plague. “Yet somehow we find it hard to believe in ones that crash down on our heads from a blue sky. There have been as many plagues as wars in history; yet plagues and wars always take people by surprise.” Camus was imagining a fictional outbreak of plague in 1948 in Oran, a port city in northwest Algeria. But at a time when the world is reeling from a very real microbial emergency sparked by the emergence of a novel coronavirus in Wuhan, central China, his observations are as pertinent a...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV health ideas Source Type: news
While the threat of the new coronavirus in the United States remains limited, a network of U.S. government agencies are already furiously ramping up efforts to contain the disease, should an outbreak occur. “We are working to keep the risk low,” said Health and Human Services Secretary Alex Azar, who is leading the federal government’s response, at a press conference Friday. So far, the overwhelming number of new cases of the virus, which originated in Wuhan, China, remain in China. There are only 11 confirmed cases in the U.S. The good news, some officials and infectious disease experts tell TIME, is t...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: news
More News: African Health | Clinical Trials | Ebola | Ebola Vaccine | Laboratory Medicine | Lessons | Outbreaks | Politics | Tropical Medicine | Uganda Health | USA Health | Vaccines